BiancoAC, KimBW. 2006. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest, 116:2571–2579.
2.
ChopraIJ. 1977. A study of extrathyroidal conversion of thyroxine (T4) to 3,3′,5-triiodothyronine (T3) in vitro. Endocrinology, 101:453–463.
3.
PeetersRP, van ToorH, KlootwijkW, de RijkeYB, KuiperGG, UitterlindenAG, VisserTJ. 2003. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab, 88:2880–2888.
4.
Cooper-KazazR, van der DeureWM, MediciM, VisserTJ, AlkelaiA, GlaserB, PeetersRP, LererB. 2009. Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J Affect Disord, 116:113–116.
5.
SchneiderMJ, FieringSN, ThaiB, WuSY, St GermainE, ParlowAF, St GermainDL, GaltonVA. 2006. Targeted disruption of the type 1 selenodeiodinase gene (Dio1) results in marked changes in thyroid hormone economy in mice. Endocrinology, 147:580–589.
6.
Piekielko-WitkowskaA, MasterA, WojcickaA, BoguslawskaJ, BrozdaI, TanskiZ, NaumanA. 2009. Disturbed expression of type 1 iodothyronine deiodinase splice variants in human renal cancer. Thyroid, 19:1105–1113.
7.
BlackDL. 2003. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem, 72:291–336.
8.
HouseAE, LynchKW. 2008. Regulation of alternative splicing: more than just the ABCs. J Biol Chem, 283:1217–1221.
9.
DiFeoA, MartignettiJA, NarlaG. 2009. The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat, 12:1–7.
10.
van AlphenRJ, WiemerEA, BurgerH, EskensFA. 2009. The spliceosome as target for anticancer treatment. Br J Cancer, 100:228–232.
11.
GerebenB, KollarA, HarneyJW, LarsenPR. 2002. The mRNA structure has potent regulatory effects on type 2 iodothyronine deiodinase expression. Mol Endocrinol, 16:1667–1679.
12.
BarthaT, KimSW, SalvatoreD, GerebenB, TuHM, HarneyJW, RudasP, LarsenPR. 2000. Characterization of the 5′-flanking and 5′-untranslated regions of the cyclic adenosine 3′,5′-monophosphate-responsive human type 2 iodothyronine deiodinase gene. Endocrinology, 141:229–237.
13.
ToyodaN, KleinhausN, LarsenPR. 1996. The structure of the coding and 5′-flanking region of the type 1 iodothyronine deiodinase (DIO1) gene is normal in a patient with suspected congenital DIO1 deficiency. J Clin Endocrinol Metab, 81:2121–2124.
14.
JakobsTC, KoehlerMR, SchmutzlerC, GlaserF, SchmidM, KohrleJ. 1997. Structure of the human type I iodothyronine 5′-deiodinase gene and localization to chromosome 1p32-p33. Genomics, 42:361–363.
15.
PachuckiJ, AmbroziakM, TanskiZ, LuczakJ, NaumanJ, NaumanA. 2001. Type I 5′-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma. J Endocrinol Invest, 24:253–261.
16.
ZhouM, RubinMA. 2001. Molecular markers for renal cell carcinoma: impact on diagnosis and treatment. Semin Urol Oncol, 19:80–87.
17.
KlatteT, PantuckAJ, KleidMD, BelldegrunAS. 2007. Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol, 9:47–56.
18.
KlatteT, SeligsonDB, LaRochelleJ, ShuchB, SaidJW, RiggsSB, ZomorodianN, KabbinavarFF, PantuckAJ, BelldegrunAS. 2009. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev, 18:894–900.
19.
HigginsJP, ShinghalR, GillH, ReeseJH, TerrisM, CohenRJ, FeroM, PollackJR, van de RijnM, BrooksJD. 2003. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol, 162:925–932.
20.
GrozovskyR, RibichS, RoseneML, MulcaheyMA, HuangSA, PattiME, BiancoAC, KimBW. 2009. Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes. Endocrinology, 150:1976–1983.
21.
VisserWE, HeemstraKA, SwagemakersSM, OzgurZ, CorssmitEP, BurggraafJ, van IjckenWF, van der SpekPJ, SmitJW, VisserTJ. 2009. Physiological thyroid hormone levels regulate numerous skeletal muscle transcripts. J Clin Endocrinol Metab, 94:3487–3496.
22.
da-SilvaWS, HarneyJW, KimBW, LiJ, BiancoSD, CrescenziA, ChristoffoleteMA, HuangSA, BiancoAC. 2007. The small polyphenolic molecule kaempferol increases cellular energy expenditure and thyroid hormone activation. Diabetes, 56:767–776.
23.
CurcioC, BaquiMM, SalvatoreD, RihnBH, MohrS, HarneyJW, LarsenPR, BiancoAC. 2001. The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. J Biol Chem, 276:30183–30187.
24.
HuangSA. 2005. Physiology and pathophysiology of type 3 deiodinase in humans. Thyroid, 15:875–881.
